The striking synergy between LAG-3 and PD-1 has been demonstrated in murine melanoma, colon cancer, and ovarian tumor models, where the dual blockade against LAG-3 and PD-1 effectively controlled tumor progression that was resistant to respective monotherapies (205, 210). This evidence concerns the gene PDCD1 and melanoma.